View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAmyris 将来の成長Future 基準チェック /26Amyrisは、44.5%と27.4%でそれぞれ年率44.5%で利益と収益が成長すると予測される一方、EPSはgrowで49.2%年率。主要情報44.5%収益成長率49.18%EPS成長率Chemicals 収益成長62.6%収益成長率27.4%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日14 Aug 2023今後の成長に関する最新情報Breakeven Date Change • Apr 17No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.Breakeven Date Change • Apr 01No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.Breakeven Date Change • Mar 25No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.Breakeven Date Change • Mar 18No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025.Breakeven Date Change • Mar 03Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 17Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.お知らせ • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.お知らせ • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.お知らせ • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.お知らせ • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Sep 08Nasdaq to Delist the Common Stock of AmyrisOn September 7, 2023, The Nasdaq Stock Market announced that it will delist the common stock of Amyris, Inc. Amyris, Inc.’s securities were suspended on August 21, 2023, and have not traded on Nasdaq since that time.お知らせ • Sep 02Amyris, Inc. Appoints Scott White as A Class II DirectorOn August 29, 2023, Amyris Inc. appointed Scott White as a Class II director, effective immediately, and with a term expiring at the company’s 2024 annual meeting of stockholders. The board determined that Mr. White qualifies as an independent director pursuant to the listing standards of the Nasdaq Stock Market. Mr. White will serve as a member of the Restructuring Committee of the Board. Mr. White is currently President and Chief Executive Officer of Edsal Manufacturing, where he has served since 2019. Mr. White has over 30 years of experience in global finance, marketing and general management roles. Prior to joining Edsal, from 2016 to 2019, Mr. White served as CEO of New Avon, a leading provider of cosmetics and beauty products. Prior to that, from 2005 to 2016, he held multiple senior management roles over 10 years at Abbott Laboratories, including President of Abbott Nutrition International. Mr. White began his career at Procter & Gamble where he served for 15 years. Mr. White currently serves as a member of the board of directors of Edsal, a privately held company. Mr. White holds an M.B.A. from Northwestern University Kellogg School of Management and a B.S. in Finance from Miami University.お知らせ • Aug 23+ 1 more updateMotion for Joint Administration Filed by Amyris, Inc.Amyris, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on August 21, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Clean Beauty Collaborative Inc., Clean Beauty 4U Holdings, LLC and Clean Beauty 4U LLC, with its own case for administrative and procedural purposes. Amyris, Inc. has been proposed as the lead debtor.お知らせ • Aug 12Amyris' Common Stock To Be Delisted from NasdaqAs previously disclosed, on August 10, 2023, Amyris, Inc. (the “Company”) and certain of its direct and indirect subsidiaries filed a voluntary petition for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. On August 10, 2023, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filings and associated public concerns raised by them, concerns regarding the residual equity interest of the existing listed securities holders and concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on August 21, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.お知らせ • Aug 11+ 4 more updatesAmyris, Inc. announced delayed 10-Q filingOn 08/10/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 27+ 1 more updateAmyris, Inc. Announces Executive ChangesAmyris, Inc. announced that John Melo has resigned from his role as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer.お知らせ • May 29Amyris Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementOn May 26, 2023, Amyris, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the ‘Minimum Bid Price Requirement’). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock which will continue to trade on The Nasdaq Global Select Market under the symbol ‘AMRS’. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 22, 2023, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by November 22, 2023, the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 22, 2023, including such options as effecting a reverse stock split.Breakeven Date Change • Apr 17No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.Breakeven Date Change • Apr 01No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.Breakeven Date Change • Mar 25No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.Breakeven Date Change • Mar 18No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025.Breakeven Date Change • Mar 03Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 17Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.お知らせ • Jan 31Amyris Launches 4U by Tia™ Haircare Line Exclusively At WalmartAmyris, Inc. announced the launch of 4U by TiaTM, a new haircare line available exclusively at Walmart. Founded by actress and entrepreneur Tia Mowry, 4U by Tia will be sold in over 2,800 Walmart retail stores in the U.S, on Walmart.com, and on the direct-to-consumer website 4UbyTia.com. Amyris will be operating the brand as part of its clean beauty portfolio of brands. The brand is launching with a full line of eight products formulated for 2A to 4C (curly) hair, all of which contain Amyris' patented Hemi15TM, a breakthrough ingredient that nourishes and protects textured hair. The line is 100% vegan, silicone-free, sulfate-free and paraben-free. Hemi15 is created using Amyris' proprietary Lab-to-Market platform, which leverages precision fermentation to create molecules that are bioidentical to those found in nature and traditionally derived from finite sources (including animals, plants, or petrochemicals) to create sustainable ingredients and provide better, healthier options for the products people use every day.Breakeven Date Change • Jan 24Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 75% is required to achieve expected profit on schedule.Breakeven Date Change • Dec 19No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.Breakeven Date Change • Nov 28No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.Breakeven Date Change • Oct 20Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.Recent Insider Transactions • Sep 08Chief Legal Officer & Secretary recently sold Mex$287k worth of stockOn the 2nd of September, Nicole Kelsey sold around 5k shares on-market at roughly Mex$57.25 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger sale from another insider worth Mex$2.4m. Insiders have been net sellers, collectively disposing of Mex$1.5m more than they bought in the last 12 months.Recent Insider Transactions • Aug 18President recently bought Mex$1.4m worth of stockOn the 15th of August, John Melo bought around 17k shares on-market at roughly Mex$80.06 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by Mex$1.1m.Breakeven Date Change • Aug 11Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.Reported Earnings • Aug 10Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.048 profit in 2Q 2021)Second quarter 2022 results: US$0.34 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$65.2m (up 25% from 2Q 2021). Net loss: US$110.0m (down US$125.4m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 91% compared to a 2.5% decline forecast for the industry in Mexico.Recent Insider Transactions • Jul 09President recently sold Mex$2.4m worth of stockOn the 6th of July, John Melo sold around 56k shares on-market at roughly Mex$44.05 per share. This was the largest sale by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.Recent Insider Transactions • Jun 06CFO & Chief Administration Officer recently sold Mex$1.6m worth of stockOn the 2nd of June, Hermanus Kieftenbeld sold around 35k shares on-market at roughly Mex$45.73 per share. This was the largest sale by an insider in the last 3 months. Hermanus has been a seller over the last 12 months, reducing personal holdings by Mex$8.8m.Board Change • Feb 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 03High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Jan 08Forecast to breakeven in 2024The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Recent Insider Transactions • Dec 12Independent Director recently bought Mex$2.1m worth of stockOn the 6th of December, James McCann bought around 17k shares on-market at roughly Mex$121 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold Mex$41m more in shares than they bought in the last 12 months.Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.37 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$47.9m (up 40% from 3Q 2020). Net loss: US$32.9m (loss narrowed 61% from 3Q 2020).Recent Insider Transactions • Sep 05CFO & Chief Administration Officer recently sold Mex$7.2m worth of stockOn the 2nd of September, Hermanus Kieftenbeld sold around 24k shares on-market at roughly Mex$297 per share. In the last 3 months, there was an even bigger sale from another insider worth Mex$30m. This was Hermanus' only on-market trade for the last 12 months.業績と収益の成長予測BMV:AMRS * - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025678-149N/A-49112/31/2024530-278N/A-223112/31/2023488-335N/A-13613/31/2023268-615-540-463N/A12/31/2022270-529-632-526N/A9/30/2022259-341-700-575N/A6/30/2022236-213-623-511N/A3/31/2022223-89-519-442N/A12/31/2021342-270-227-181N/A9/30/2021357-417-74-49N/A6/30/2021343-467-48-35N/A3/31/2021321-585-35-21N/A12/31/2020173-382-189-176N/A9/30/2020134-351-223-209N/A6/30/2020135-325-222-209N/A3/31/2020167-293-177-166N/A12/31/2019153-270-170-157N/A9/30/2019128-240-149-133N/A6/30/2019108-258-127-113N/A3/31/201960-202-135-121N/A12/31/201864-223-122-109N/A9/30/2018112-287-98-88N/A6/30/2018122-253-104-95N/A3/31/2018133-250-106-101N/A12/31/2017128-202-106-101N/A9/30/201785-139-140-140N/A6/30/201787-116-104-104N/A3/31/201771-119-85-84N/A12/31/201667-97N/A-82N/A9/30/201655-94N/A-78N/A6/30/201637-151N/A-91N/A3/31/201635-185N/A-106N/A12/31/201534-222N/A-85N/A9/30/201536-118N/A-73N/A6/30/201544-78N/A-82N/A3/31/201545-66N/A-78N/A12/31/2014432N/A-85N/A9/30/201447-195N/A-101N/A6/30/201438-183N/A-96N/A3/31/201439-186N/A-92N/A12/31/201341-235N/A-106N/A9/30/201332-139N/A-101N/A6/30/201344-135N/A-105N/A3/31/201352-143N/A-113N/A12/31/201274-205N/A-151N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AMRS *今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: AMRS *今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: AMRS *今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: AMRS *の収益 ( 27.4% ) MX市場 ( 6.1% ) よりも速いペースで成長すると予測されています。高い収益成長: AMRS *の収益 ( 27.4% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AMRS *の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/11/15 07:46終値2023/08/18 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Amyris, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15 アナリスト機関J. HorwitzBairdCarter DriscollB. Riley Securities, Inc.Susan AndersonCanaccord Genuity12 その他のアナリストを表示
Breakeven Date Change • Apr 17No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.
Breakeven Date Change • Apr 01No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.
Breakeven Date Change • Mar 25No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.
Breakeven Date Change • Mar 18No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025.
Breakeven Date Change • Mar 03Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 17Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
お知らせ • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.
お知らせ • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.
お知らせ • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.
お知らせ • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.
お知らせ • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Sep 08Nasdaq to Delist the Common Stock of AmyrisOn September 7, 2023, The Nasdaq Stock Market announced that it will delist the common stock of Amyris, Inc. Amyris, Inc.’s securities were suspended on August 21, 2023, and have not traded on Nasdaq since that time.
お知らせ • Sep 02Amyris, Inc. Appoints Scott White as A Class II DirectorOn August 29, 2023, Amyris Inc. appointed Scott White as a Class II director, effective immediately, and with a term expiring at the company’s 2024 annual meeting of stockholders. The board determined that Mr. White qualifies as an independent director pursuant to the listing standards of the Nasdaq Stock Market. Mr. White will serve as a member of the Restructuring Committee of the Board. Mr. White is currently President and Chief Executive Officer of Edsal Manufacturing, where he has served since 2019. Mr. White has over 30 years of experience in global finance, marketing and general management roles. Prior to joining Edsal, from 2016 to 2019, Mr. White served as CEO of New Avon, a leading provider of cosmetics and beauty products. Prior to that, from 2005 to 2016, he held multiple senior management roles over 10 years at Abbott Laboratories, including President of Abbott Nutrition International. Mr. White began his career at Procter & Gamble where he served for 15 years. Mr. White currently serves as a member of the board of directors of Edsal, a privately held company. Mr. White holds an M.B.A. from Northwestern University Kellogg School of Management and a B.S. in Finance from Miami University.
お知らせ • Aug 23+ 1 more updateMotion for Joint Administration Filed by Amyris, Inc.Amyris, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on August 21, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Clean Beauty Collaborative Inc., Clean Beauty 4U Holdings, LLC and Clean Beauty 4U LLC, with its own case for administrative and procedural purposes. Amyris, Inc. has been proposed as the lead debtor.
お知らせ • Aug 12Amyris' Common Stock To Be Delisted from NasdaqAs previously disclosed, on August 10, 2023, Amyris, Inc. (the “Company”) and certain of its direct and indirect subsidiaries filed a voluntary petition for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. On August 10, 2023, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filings and associated public concerns raised by them, concerns regarding the residual equity interest of the existing listed securities holders and concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on August 21, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.
お知らせ • Aug 11+ 4 more updatesAmyris, Inc. announced delayed 10-Q filingOn 08/10/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 27+ 1 more updateAmyris, Inc. Announces Executive ChangesAmyris, Inc. announced that John Melo has resigned from his role as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer.
お知らせ • May 29Amyris Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementOn May 26, 2023, Amyris, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the ‘Minimum Bid Price Requirement’). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock which will continue to trade on The Nasdaq Global Select Market under the symbol ‘AMRS’. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 22, 2023, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by November 22, 2023, the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 22, 2023, including such options as effecting a reverse stock split.
Breakeven Date Change • Apr 17No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.
Breakeven Date Change • Apr 01No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.
Breakeven Date Change • Mar 25No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025.
Breakeven Date Change • Mar 18No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025.
Breakeven Date Change • Mar 03Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 17Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
お知らせ • Jan 31Amyris Launches 4U by Tia™ Haircare Line Exclusively At WalmartAmyris, Inc. announced the launch of 4U by TiaTM, a new haircare line available exclusively at Walmart. Founded by actress and entrepreneur Tia Mowry, 4U by Tia will be sold in over 2,800 Walmart retail stores in the U.S, on Walmart.com, and on the direct-to-consumer website 4UbyTia.com. Amyris will be operating the brand as part of its clean beauty portfolio of brands. The brand is launching with a full line of eight products formulated for 2A to 4C (curly) hair, all of which contain Amyris' patented Hemi15TM, a breakthrough ingredient that nourishes and protects textured hair. The line is 100% vegan, silicone-free, sulfate-free and paraben-free. Hemi15 is created using Amyris' proprietary Lab-to-Market platform, which leverages precision fermentation to create molecules that are bioidentical to those found in nature and traditionally derived from finite sources (including animals, plants, or petrochemicals) to create sustainable ingredients and provide better, healthier options for the products people use every day.
Breakeven Date Change • Jan 24Forecast to breakeven in 2025The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
Breakeven Date Change • Dec 19No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.
Breakeven Date Change • Nov 28No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.
Breakeven Date Change • Oct 20Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
Recent Insider Transactions • Sep 08Chief Legal Officer & Secretary recently sold Mex$287k worth of stockOn the 2nd of September, Nicole Kelsey sold around 5k shares on-market at roughly Mex$57.25 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger sale from another insider worth Mex$2.4m. Insiders have been net sellers, collectively disposing of Mex$1.5m more than they bought in the last 12 months.
Recent Insider Transactions • Aug 18President recently bought Mex$1.4m worth of stockOn the 15th of August, John Melo bought around 17k shares on-market at roughly Mex$80.06 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by Mex$1.1m.
Breakeven Date Change • Aug 11Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
Reported Earnings • Aug 10Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.048 profit in 2Q 2021)Second quarter 2022 results: US$0.34 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$65.2m (up 25% from 2Q 2021). Net loss: US$110.0m (down US$125.4m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 91% compared to a 2.5% decline forecast for the industry in Mexico.
Recent Insider Transactions • Jul 09President recently sold Mex$2.4m worth of stockOn the 6th of July, John Melo sold around 56k shares on-market at roughly Mex$44.05 per share. This was the largest sale by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.
Recent Insider Transactions • Jun 06CFO & Chief Administration Officer recently sold Mex$1.6m worth of stockOn the 2nd of June, Hermanus Kieftenbeld sold around 35k shares on-market at roughly Mex$45.73 per share. This was the largest sale by an insider in the last 3 months. Hermanus has been a seller over the last 12 months, reducing personal holdings by Mex$8.8m.
Board Change • Feb 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 03High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Jan 08Forecast to breakeven in 2024The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Recent Insider Transactions • Dec 12Independent Director recently bought Mex$2.1m worth of stockOn the 6th of December, James McCann bought around 17k shares on-market at roughly Mex$121 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold Mex$41m more in shares than they bought in the last 12 months.
Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.37 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$47.9m (up 40% from 3Q 2020). Net loss: US$32.9m (loss narrowed 61% from 3Q 2020).
Recent Insider Transactions • Sep 05CFO & Chief Administration Officer recently sold Mex$7.2m worth of stockOn the 2nd of September, Hermanus Kieftenbeld sold around 24k shares on-market at roughly Mex$297 per share. In the last 3 months, there was an even bigger sale from another insider worth Mex$30m. This was Hermanus' only on-market trade for the last 12 months.